Telephone
N/A
Address
North Melbourne Suite 401 55 Flemington Road Melbourne, Victoria (VIC) 3051
Description
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TX250, TX591, and TX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 5.82 - 12.79
Trade Value (12mth)
AU$2,570,042.00
1 week
5.25%
1 month
10.7%
YTD
37.23%
1 year
31.96%
All time high
12.79
EPS 3 yr Growth
180.600%
EBITDA Margin
-42.40%
Operating Cashflow
-$64m
Free Cash Flow Return
-136.30%
ROIC
-221.70%
Interest Coverage
-167.00
Quick Ratio
1.90
Shares on Issue (Fully Dilluted)
318m
HALO Sector
Healthcare
Next Company Report Date
26-Feb-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
1.66
Date | Announcements |
---|---|
31 May 18 |
CEO presentation to Wilsons Rapid Insights Conference
×
CEO presentation to Wilsons Rapid Insights Conference |
31 March 22 |
Change of Composition of the Telix Board of Directors
×
Change of Composition of the Telix Board of Directors |
31 March 22 |
Appendix 3X - Initial Directors Interest Notice
×
Appendix 3X - Initial Directors Interest Notice |
31 January 22 |
App 3Y Change of Directors Interest Notice - C Behrenbruch
×
App 3Y Change of Directors Interest Notice - C Behrenbruch |
31 January 22 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
31 January 22 |
Notice of change of interests of substantial holder
×
Notice of change of interests of substantial holder |
31 January 22 |
Cleansing Notice under S708A(5)(e) Corporations Act 2001
×
Cleansing Notice under S708A(5)(e) Corporations Act 2001 |
31 January 22 |
Notice of change of interests of substantial holder
×
Notice of change of interests of substantial holder |
31 January 22 |
App 3Y Change of Directors Interest Notice - A Kluge
×
App 3Y Change of Directors Interest Notice - A Kluge |
31 January 22 |
Despatch of SPP Booklet to Eligible Shareholders
×
Despatch of SPP Booklet to Eligible Shareholders |
30 May 23 |
Securities Dealing Policy - updated
×
Securities Dealing Policy - updated |
30 May 22 |
Illuccix Reimbursement Milestone and Launch Updates
×
Illuccix Reimbursement Milestone and Launch Updates |
30 December 22 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
30 December 22 |
Cleansing Notice
×
Cleansing Notice |
29 March 23 |
Non-Executive Director Leave of Absence
×
Non-Executive Director Leave of Absence |
29 March 22 |
Telix and Xiel Sign U.K. and Ireland Distribution Agreement
×
Telix and Xiel Sign U.K. and Ireland Distribution Agreement |
29 March 22 |
FDA Orphan Drug Designation for Bone Marrow Conditioning
×
FDA Orphan Drug Designation for Bone Marrow Conditioning |
29 August 22 |
Notification of cessation of securities - TLX
×
Notification of cessation of securities - TLX |
29 August 22 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
29 August 22 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
28 September 22 |
Telix Withdraws Marketing Application for Illuccix in Europe
×
Telix Withdraws Marketing Application for Illuccix in Europe |
28 September 22 |
Chinese NMPA Approves TLX250 Phase III registration study
×
Chinese NMPA Approves TLX250 Phase III registration study |
28 November 22 |
Release of shares from voluntary escrow
×
Release of shares from voluntary escrow |
28 November 22 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
28 November 22 |
Cleansing Notice
×
Cleansing Notice |
28 June 23 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
28 June 23 |
Cleansing Notice
×
Cleansing Notice |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.